Enzyplex tablet samples checked by the Department of Health have met pharmacopoeial standards and the in-house specifications set by the Indonesian manufacturer on mould and yeast content.

Samples were collected from various sources for analysis on June 21 due to suspected mould contamination.

However, an earlier test found the bacterial content of samples exceeded the in-house specifications even though they passed pharmacopoeial standards.

The local supplier Unam recalled all batches of Enzyplex tablet on June 26.

The department has also instructed Unam to ask the manufacturer to submit an investigation report as soon as possible.

The department has not received any adverse drug reaction reports in connection with the product so far.